{"title": "COVID-19 roundup: New omicron subvariants may be up to 21x more evasive against vaccine antibodies", "author": null, "url": "https://www.advisory.com/daily-briefing/2023/01/20/covid-19-roundup", "hostname": "advisory.com", "description": "FDA cautions that Evusheld may not be effective against the XBB.1.5 omicron subvariant, new studies suggest the coronavirus may be able to survive in infected patients even after death, and more in this week's roundup of COVID-19 news.", "sitename": "advisory.com", "date": "2023-01-20", "cleaned_text": "FDA cautions that Evusheld may not be effective against the XBB.1.5 omicron subvariant, new studies suggest the coronavirus may be able to survive in infected patients even after death, and more in this week's roundup of COVID-19 news. Create your free account to access 2 resources each month, including the latest research and webinars. You have 2 free members-only resources remaining this month remaining this month. Never miss out on the latest innovative health care content tailored to you. "}